Fig. 4: In vitro ibrutinib treatment shows no direct effects on CD40-induced venetoclax resistance or Bcl-2 family member expression. | Leukemia

Fig. 4: In vitro ibrutinib treatment shows no direct effects on CD40-induced venetoclax resistance or Bcl-2 family member expression.

From: Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Fig. 4

In vitro experiments using 0.1 µM ibrutinib for 24 h showed no direct effects of ibrutinib on A venetoclax sensitivity (N = 14), B immunological detection of CD95 (N = 11) and (C–E) and Bcl-2 family proteins (N = 12) as seen in vivo. Paired sample t-test was used for statistical analyses.

Back to article page